Pituitary Adenoma & Sellar Lesions

1.Dose for control

For a nonfunctioning adenoma the objective is tumor control, achieved at modest marginal doses: commonly 14–16 Gy. In the ISRS practice opinion and pooled series, single-fraction SRS at a median margin dose of 15 Gy yields tumor control of about 94% at 5 years and 83% at 10 years. SRS is typically applied to residual/recurrent tumor with a safe optic separation; juxta-chiasmatic residual is treated with fractionated SRT instead.

2.Higher dose, slower remission, drug timing

Secreting tumors: GH-secreting (acromegaly), ACTH-secreting (Cushing disease), prolactinomas, and others: require higher marginal doses, on the order of 18–30 Gy, to achieve biochemical remission, and even then endocrine normalization accrues over several years with remission rates lower than the tumor-control rates of nonfunctioning tumors. Radiologic tumor control is high across subtypes and usually accompanies, but can outpace, biochemical remission.

Subtype-specific expectations from pooled SRS series: Cushing disease reaches endocrine remission in roughly 35–65% of patients: crude pooled multicenter estimates sit near 48%, while actuarial series report higher figures, including 80% initial and 64% durable control of hypercortisolism at 10 years. Remission typically arrives within 1–3 years, but durable cure requires lifelong surveillance because late recurrence of hypercortisolism is well described. Acromegaly achieves IGF-1 / OGTT-defined remission in roughly 40–45% at 5 years, rising to about 55–60% at 10 years, with a similar multi-year latency. Prolactinomas show the lowest reported remission rates, on the order of 25–50%. Part of that gap is selection rather than radiobiology, since SRS reaches prolactinomas only after dopamine agonists and surgery have failed, which enriches the treated group for aggressive tumors.

Antisecretory medication is usually withdrawn before treatment. The ISRS practice recommendations favor withdrawal, typically 4 to 12 weeks before radiosurgery, when the patient's endocrine status makes that safe. The supporting evidence is retrospective and inconsistent: cessation of IGF-1-lowering therapy was the only independent predictor of durable remission in the multicenter acromegaly cohort, whereas the multicenter Cushing cohort found no effect. Any interruption of somatostatin analogs, dopamine agonists, or cortisol-lowering therapy should therefore be planned with endocrinology, balancing a theoretical radiobiologic advantage against the danger of uncontrolled hormone excess. Prolactinomas remain medical-first; SRS is reserved for resistant, intolerant, or aggressive disease.

3.What to protect, and what fails over time

The complications that matter:

• Optic neuropathy: the dose-limiting risk. Keeping the optic apparatus maximum dose at or below 10 Gy in a single fraction holds radiation-induced optic neuropathy to about 1% in patients with no prior irradiation, with D0.2cc under 8 Gy. Risk stays low to roughly 12 Gy and climbs materially in the 12–15 Gy range. Prior irradiation raises risk about tenfold and warrants a tighter limit.
• Hypopituitarism: the commonest late effect. Reported rates run about 10–25% at 5 years and 15–40% at 10 years depending on era and stalk dose, with new deficits appearing at a median of roughly 2–4 years and continuing to accrue past a decade. Risk is reduced by limiting dose to the normal gland and stalk: in the largest multicenter series a maximum point dose above 10 Gy to the pituitary stalk tripled the hazard of new hormone deficiency, so keep stalk maximum dose under 10 Gy where target coverage allows. Lifelong endocrine surveillance is mandatory.
• Cranial neuropathy: uncommon; the cavernous-sinus cranial nerves are relatively radioresistant, and carotid injury is rare.

4.What the evidence settles, and what it does not

Pituitary radiosurgery rests on large multicenter cohorts rather than randomized trials; the open questions are about technique and timing, not whether SRS works.

Open controversies:

• Single-fraction SRS versus fractionated SRT for perioptic tumors. When the tumor abuts the optic apparatus, the choice between hypofractionation and conventional SRT, and where exactly to draw the distance threshold, varies by center.
• The antisecretory-drug question. Retrospective signals support holding selected agents in some patients, but the effect is inconsistent and the optimal timing is unknown. Endocrine safety takes priority over a routine medication holiday.
• Optimal dose for functioning adenomas. Higher margin doses speed remission but raise hypopituitarism risk; the best balance for each secretory subtype is unsettled.
• Nonfunctioning residual: treat or observe. Whether to irradiate a small postoperative remnant promptly or follow it and treat on growth is a genuine judgment call.